glp-1 agonist fda approval The #FDA approved the first oral receptor agonist, semaglutide (#Wegovy pill), for chronic weight management in adults with obesity or overweight with comorbidities, offering a noninjectable alternative with significant weight loss Size:120 Capsules non-affirm Key FDA approval (April

glp-1 agonist fda approval The #FDA approved the first oral receptor agonist, semaglutide (#Wegovy pill), for chronic weight management in adults with obesity or overweight with comorbidities, offering a noninjectable alternative with significant weight loss Size:120 Capsules non-affirm Key FDA approval (April

Key FDA approval (April 2026) FDA approved orforglipron (Foundayo) - first oral non-peptide GLP-1 receptor agonist Indication: chronic weight management in adults with obesity OR overweight + ≥1 comorbidity Must be combined

YC: Conceptualization, Writing – review and editing

non-affirm

Size:120 Capsules

1994;267(5 pt 1):E662–E671